1. 295] 21. Ilett KF, Tee LBG, Reeves PT, et al. Metabolism of drugs and other xenobiotics in the gut lumen and wall. Pharmacol Ther 1990; 46(1):67–93. 22. Paine MF, Khalighi M, Fisher JM, et al. Characterization of interintestinal and intraintestinal variations in human cyp3a-dependent metabolism. J Pharmacol Exp Ther 1997; 283(3):1552–1562. 23. Nyberg L, Mansson W, Abrahamsson B, et al. A convenient method for local drug administration at predefined sites in the entire gastrointestinal tract: experiences from 13 phase I studies. Eur J Pharm Sci 2007; 30(5):432–440. 24. Dressman JB, Kra¨mer J, eds. Pharmaceutical Dissolution Testing. Boca Raton: Taylor & Francis, 2005. 25. Blanquet S, Zeijdner E, Beyssac E, et al. A dynamic artificial gastrointestinal system for studying the behavior of orally administered drug dosage forms under various physiological conditions. Pharm Res 2004; 21(4):585–591. 26. Sandberg A, Abrahamsson B, Sjo¨gren J. Influence of dissolution rate on the extent and rate of bioavailability of metoprolol. Int J Pharm 1991; 68(1–3):167–177. 27. Ko¨rner A, Larsson A, Piculell L, et al. Tuning the polymer release from hydrophilic matrix tablets by mixing short and long matrix polymers. J Pharm Sci 2005; 94(4): 759–769. 28. Bisrat M, Anderberg EK, Barnett MI, et al. Physicochemical aspects of drug release. XV. Investigation of diffusional transport in dissolution of suspended, sparingly soluble drugs. Int J Pharm 1992; 80(2–3):191–202. 29. Freitas MP, Sabadin A, Silva LM, et al. Prediction of drug dissolution profiles from tablets using NIR diffuse reflectance spectroscopy: a rapid and nondestructive method. J Pharm Biomed Anal 2005; 39(1–2):17–21. 30. Bergman E, Forsell P, Persson EM, et al. Pharmacokinetics of gefitinib in humans: the influence of gastrointestinal factors. Int J Pharm 2007; 341(1–2):134–142. 31. Abrahmsen-Alami S, Ko¨rner A, Nilsson I, et al. New release cell for NMR microimaging of tablets Swelling and erosion of poly(ethylene oxide). Int J Pharm 2007; 342 (1–2):105–114. 32. Klein S, Stein J, Dressman J. Site-specific delivery of anti-inflammatory drugs in the gastrointestinal tract: an in-vitro release model. J Pharm Pharmacol 2005; 57(6): 709–719. 33. Boni JE, Brickl RS, Dressman J. Is bicarbonate buffer suitable as a dissolution medium? J Pharm Pharmacol 2007; 59(10):1375–1382. 34. Kalantzi L, Goumas K, Kalioras V, et al. Characterization of the human upper gastrointestinal contents under conditions simulating bioavailability/bioequivalence studies. Pharm Res 2005; 23:165–176. 35. Galia E, Nicolaides E, Ho¨rter D, et al. Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs. Pharm Res 1998; 15:698–705. 36. Sheng J. Toward an in vitro bioequivalence test (PhD). University of Michigan, Ann Arbor, 2007. 37. Weitschies W, Wedemeyer R-S, Kosch O, et al. Impact of the intragastric location of extended release tablets on food interactions. J Control Release 2005; 108:375–385. 38. Doelker E. Cellulose derivatives. Adv Polym Sci 1993; 107:199–265. 39. Mitchell K, Ford JL, Armstrong DJ, et al. The influence of concentration on the release of drugs from gels and matrices containing methocel. Int J Pharm 1993; 100(1–3):155– 163. 40. Abrahamsson B, Alpsten M, Bake B, et al. In vitro and in vivo erosion of two different hydrophilic gel matrix tablets. Eur J Pharm Biopharm 1998; 46:69–75. 41. Lo¨froth JE, Johansson L, Norman AC, et al. Interactions between surfactants and polymers. I: HPMC. Prog Colloid Polym Sci 1991; 84:73–77. 42. Abrahamsson B, Johansson D, Torstensson A, et al. Evaluation of solubilizers in the drug release testing of hydrophilic matrix extended-release tablets of felodipine. Pharm Res 1994; 11(8):1093–1097. 43. Lindstedt B, Ragnarsson G, Hjartstam J. Osmotic pumping as a release mechanism for membrane-coated drug formulations. Int J Pharm 1989; 56(3):261–268. Forms X [2/2/010/16:57:51] [265 –